Protagonist Therapeutics Earned $10M Milestone Payment From Johnson & Johnson Following The Dosing Of The Third Patient In Phase 2b ANTHEM-UC Trial Of JNJ-2113 Compared With Placebo For Moderate To Severe Active Ulcerative Colitis
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics received a $10M milestone payment from Johnson & Johnson after the third patient was dosed in the Phase 2b ANTHEM-UC trial of JNJ-2113 for moderate to severe active ulcerative colitis.
December 13, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's collaboration with Protagonist Therapeutics progresses with the dosing of the third patient in a key trial, which could have a modest positive impact on JNJ's stock.
While the milestone payment is a routine part of such collaborations, it indicates that the trial is advancing as planned, which could be seen as a positive development for JNJ. However, given JNJ's size and diversified portfolio, the impact on its stock price may be less pronounced compared to PTGX.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 70
POSITIVE IMPACT
Protagonist Therapeutics received a significant milestone payment, which may positively impact its financials and investor sentiment in the short term.
The milestone payment is a positive financial development for Protagonist Therapeutics and indicates progress in their collaboration with Johnson & Johnson. This news is likely to be viewed favorably by investors and could lead to a short-term increase in PTGX's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90